Method of producing cephalosporins

专利摘要:
Cephalosporin compounds substituted in the 7-position by a 2-(5- or 6-membered heterocyclic)-2-oximinoacetylamino group and of the formula <CHEM> in which R is hydrogen, formyl, alpha -aminoadipoyl, protected alpha -aminoadipoyl, or an acyl group of the formula <CHEM> in which R min is a 5- or 6-membered heterocyclic ring of the formulae <CHEM> R sec is hydrogen, C1-C4 alkyl, a carboxy-substituted alkyl or carboxy-substituted cycloalkyl group of the formula: <CHEM> in which n is 0-3; a and b when taken separately are, independently, hydrogen or C1-C3 alkyl, and when taken together with the carbon to which they are bonded form a C3-C7 carbocyclic ring; R''' is hydrogen, C1-C4 alkoxy, amino, or OR<0>, in which R<0> is indanyl, phthalidyl or an acyloxymethyl group of the formula -CH2-O-C(O)-R2 in wich R2 is C1-C4 alkyl or phenyl; or COOR<0> is a protected carboxy group; or R sec is an N-substituted carbamoyl group of the formula -@-NHR sec sec in which R sec sec is C1-C4 alkyl, phenyl or C1-C3 alkyl substituted by phenyl; Y and m, independently, are integers equal to 0, 1, 2 or 3, provided that y plus m equals 3; R<1> is hydrogen, C1-C4 alkyl, phenyl, thienyl, amino or C1-C4 alkanoylamino; X is O, S or N-R<2>, where R<2> is hydrogen or C1-C4 alkyl; or a pharmaceutically-acceptable salt or biologically-cleavable ester thereof.
公开号:SU1360587A3
申请号:SU843798239
申请日:1984-10-12
公开日:1987-12-15
发明作者:Самуэль Катнер Аллен
申请人:Эли Лилли Энд Компани (Фирма)；
IPC主号:

专利说明:

ten
This invention relates to a method for producing new cephalosporin antibiotics that can be used as medicines in medicine.
. The aim of the invention is to create new cephalosporins, which have a stable antibiotic action against a wide range of modified strains of organisms in the absence of side effects.
In the examples below, the following abbreviations are used: CIH refers to trimethylsryl iodide; THF is tetrahydrofuran; HPLC refers to high performance liquid chromatography; NMR - nuclear magnetic resonance spectrum; DMSO-d is deuterated dimethyl sulfoxide; 20 and the symbols describing the NMR signals denote the following: с - singlet, -. doublet; q - quartet; m - multi years; t is a triplet; Pts - highly; ir - wide. NMR spectra were obtained on a IOELFX-90 instrument.
Example 1. Shin-7-G2- (2-aminoazole-4-Sh1) -2- (2-carboxyxyprop-2-yl) oxnimoacetamido} -3- (Sh-imidazolo 4,5-cycridine-3- ylmethyl) -3-cephem-4-carboxylate,
To a suspension of 1.34 g (2.5 mmol) syn-7- 2- (2-aminothiazol-4-yl) -2- (-t-butoxycarbonylprop-2-yl) oxyimino-acetamido) -3 J-acetoxymethyl - 3-cephem-4-carbonic acid in 15 ml of dichloromethane was added in one portion of 1.42 MP (8 mmol) of N-methyl-I-trimethyl-silyltriftsroacetamide. The reaction mixture is stirred for 5 minutes under nitrogen. 0.88 ml (6.2 mmol) of trimethyl iodo-15 is pipetted to the stirred solution.
Qfl
35
25

the silane and the reaction mixture is then stirred at 25 ° C for 30 minutes. The solvent is removed by evaporation under reduced pressure and an oil is obtained. The oil is dissolved in 6 ml of acetonitrile and 0.84 ml (10.3 mmol) of tetrahydrofuran and the solution is stirred for 5 minutes, after which a solution of 325 mg (2.7 mmol) of 1H-1 is added in one portion. imidazolo (4,5-c) pyridine with 2 ml of acetonitrile containing 1 ml of N-methyl-K-trimethylsilyl trifluoroacetamide. The reaction mixture is stirred for 3 hours at and then 60 ml of diethyl ether, 35 ml of acetone and 5 ml of methanol are added to the mixture. Precipitated
0
the solid is collected by filtration to obtain 630 mg (yield 23%) of the product as a solid. The solid is purified by high-performance liquid chromatography: on silica gel with reversed phase Cjg using a mixture of acetonitrile - acetic acid - water (10-2-88% by volume) as a crucible.
Removal of solvents from the appropriate fractions gives 120 mg of syn-7- 2- (2-amino-thiaaol-4-yl) -2-carbodssi-) oxyiminoacetamido} -3- (1H-5 imidazolo 4,5-c pyridine-5- Ilmetsh1) - Zz of efem-4-carboxylate.
IR spectrum (kVg): 1776 cm / s, - lakam;
UV spectrum. (EtOH) 220, E 37000; , M Theory 586; found 586; The NIR spectrum of GDMSO-dj): signals at 9.75 (s, 1H) s / 9.5 (d, W); 8.1 (d, 1H); 8.7 (d, 1H); 7.1 (broad s, 2H); 6.7 (s, 1H); 5.7 (m, 1H), 15 (d, 1K); 1.4 (s, 6H).
PRI mme R 2. Sin-7- 2- (2-aminothiazol-4-yl) -2-methoxyiminoacetamido} -3- (1H-imidazolo 4,5-c pyridine 5-ylmethyl) - 3-cephem-4-carboxylate,
fl)
Suspension 910 mg (2 mmol) syn- 7-G2- (2-amino thiaz ol-4-yl) 2-labels syminoacetamido Z-3-acetoxymethyl-3; cephem-4-carboxylic acid in 3 ml of dichloromethane containing 1.24 ml of 5 (7 mmol) N-methyl-N-trimethylsilyl-trifluoroacetamide is heated to 40 ° C and sonicated for 5 minutes. The reaction mixture is cooled; (,
five
give up to 25 C and stirred at one
 adding 0.77 ml (5.4 mmol) of trimethyl yodosilane over time, and then over-rolling is continued for 30 minutes. The solvent is removed by drilling under reduced
5 and the oil is dissolved in 3 ml of acetonitrile and 0.77 ml (9 mmol). tetrahydrofuran. To this reaction mixture was added a solution of 297 mg (2.5 mmol) of 1H-imidazolo (4,5-c) pi-
0 Ridine in 12.ml acetonitrile containing 1.5 ml of M-methyl-N-trimethylsilyl trifluoroacetamide. The reaction mixture was stirred at 25 ° C for 3 hours and then added to 50 mp
5 95% acetone-methanol (v / v). The precipitated solid is collected by filtration (yield 1.09 g) and purified by reverse-phase HPLC 1360587 .-.
ZOY C, g on silica gel using an ac-IR spectrum (KBr): 1773 cm - / j-lactam;
M Theory 529; found 529. LIR spectrum (DMSO-th): signals at
tonitrylacetic acid - water (4-2-94 percent by volume). 390 mg of syn-7-G .- (2-aminothiazol4-yl) -2-methoxyiminoacetamido-3- (1H-, (s, III); 9.45 (d, 1H); 9.1 imidazolo-4,5 are obtained cJ pyridinium-5-ylmethyl) -3-cephem-4-carboxylate.
IR spectrum (KBG): 1772 cm- / -lakstam;
UV spectrum (E ± OH) I
M «Kc212, f 34000;
M Theory 515; found 515;
NMR spectrum (DMSO-d): signals at s / 9.85 (s, 1H); 9.55 (d, 1H); 8.9 (d, 1H); 8.8 (s, 1H); 8.15 (d, 1H); 7.2 (broad s, 2H); 6-, 7 (s, 1H); 5.7 (m, 1H); 5.15 (d, W); 3.8 (s, ZN).
PRI me R 3. Sin-7- 2- (2-amino-thiazol-4-yl) -2-methoxy-imino-acetamido-3- (3-methyl-3N-nmidazolo G 4, 5-c 3 -pyridinium- 5-ylmetrySh1} 3-cephem-4-carboxylate is prepared analogously to example 2 by reacting 910 mg (2 mmol) of syn- (2-aminothiazol-4-yl) -2-methoxy-
(d, 1H); 8.8 (s, Ш); 8.3 (d, 1H); , 7.15 (shooting range, 2H); 6.65 (s, 1H); 5.65 (m, W); 5.05 (m, 1H); 4.0 (s, 10 MN); 3.75 (s, ZN).
PRI me R 5. Sin-7-G2- (2-amino-thiazol-4-yl) -2-methoxyimino-dedetam-7-3- (2-methyl-1H-imidazolo G4,5-c pyridine-5- ylmethyl) -3-cephem-4-carb-15 oxylate. Yield 96%.
NMR (DMSO-dJ: signals at (/ 9.9 (s, 1H); 9.5 (d, W); 8.85 (, W); 8.05 (d, 1H); 7.1 ( broad s, 2H); 6.66
20
(s, 1H); 5.7 (m, W); 5.1 (d, W); 3.75 (s, 3N); 2.7 (s, ZN).
Example Syn-7-f2- (2-amino-thiazol-4-yl) -2-methoxyimino acetates to -3- (1,2-dimethyl-1 H-imidazole C4,5- with pyridinium-5-ylmetsh1) -3- cefem-4-
iminoacetamido-3-adhetoxymethyl-4-25 carboxylate. Yield 80%.
carboxylic acid with 1.24 ml (7.0 mmol / IR spectrum (KBG): 1774 cm. / 3-lac N-methyl-K-trimethylsilyl trifluoroethylene-)
amide and 0.77 ml (5.4 mmol) of trimethyl-iodosilane to obtain the corresponding 3-iodomethyldephalosporin and contact the latter compound in situ with 3-methyl-3N-imidazolo with 4,5-epyridine. Get the product in the form. 920 mg of white solid. Wipe
there;
UV spectrum (EtOH)., Kc218, f 48500.
51MP spectrum (DMSO-d g):. signals at 30 9.8 (s, 1H); 9.5 (d, 1H); 9.1 Sd, Sh); 8.2 (d, 1H); 7.15 (broad s, 2H); 6.65 (s, 1H); 5.6 (m, 1H); 5.05 (m, 1H); 3.9 (s, ZN.); 3.75 (s, 3N); 2.7 (s, ZN).
51MP spectrum (DMSO-d g):. signals at 30 9.8 (s, 1H); 9.5 (d, 1H); 9.1 Sd, Sh); 8.2 (d, 1H); 7.15 (broad s, 2H); 6.65 (s, 1H); 5.6 (m, 1H); 5.05 (m, 1H); 3.9 (s, ZN.); 3.75 (s, 3N); 2.7 (s, ZN).
Example 7. Syn-7-G2- (2-amino acid by means of highly efficient
reverse chromatography with 35 thiazol-4-yl) -2-methoxyiminoacetamidase C1 gives 340 mg of the title compound (2,3-dimesh1-ZN-imidazolo 4,5c 3 pyridinium-5-ylmethyl) -3-cephem -4- carboxylate. Yield 53%.
IR spectrum (KBG): 1775 cm lacquer.
G-spectrum (KVg): 1772 cm; UV spectrum. (EtOH) ... 210, -e 36500;
40
  U
M Theory 529; found 529;
NMR spectrum (DMSO-d): signals at W 9.5 (d, 1H); 9.4 (d, 1H) ;, 9.05 (s, Sh); 8.35 (d, W); 7.2 (broad s, 2H); 6.73 (s, Ш); 5.75 (m, 1H); 5.15 (d, 1H); 4.15 (s, 3N); 3.83 (s, RN).,
The following 3-bicyclic pyridinium methyl cephalosporins of examples 4-16 are prepared analogously to the methods of examples 1-3 by the reaction of bicyclic pyridine With 3-iodomethyl cephalosporin obtained from the corresponding 3-acetoxymethyl cephalosporin derivative.
there;
UV spectrum (EtOH) 206, 38000;
M Theory 543; found 543.
NMR spectrum (flWCO-dg): signals at (, 9 (s, 1H); 9.5 (d, 1H); 9.3 (d, Sh); 8.1 (d, Sh); 7.15 (broad s, 2H); 6.7 (s, 1H); 5.7 (m, 1H); 5.1 (d, 1H); 3.95 (s, 3N); 3.8 (s, ZN); 2.8 (s, ZN).
EXAMPLE 8 Sin-7-G2- (2-amino-thiazol-4-yl) -2-methoxyiminoacetamido-3-G5- (2-thienyl) -1H-imidazolo, 4,5- with pyridinium-5-methyl-3-cephem-EXAMPLE 4. Sin-7- 2- (2-amino-gs carboxylate. Yield 18.7%.
JK-spectrum (KBg): 1774 cm -lamps;
thiazol-4-yl) -2-methoxyiminoacetam- (1-meth yl-1H-imidaz, ridiniy-5-ylmethyl) -3-cephem-4-carboxylate. Yield 86%.
UV spectrum (BION) L ",., 247, e 25500;
MSWSS
m Theory 596; found 597.
, (s, Ш); 9.45 (d, 1H); 9.1
(d, 1H); 8.8 (s, Ш); 8.3 (d, 1H); , 7.15 (shooting range, 2H); 6.65 (s, 1H); 5.65 (m, W); 5.05 (m, 1H); 4.0 (s, 3N); 3.75 (s, ZN).
PRI me R 5. Sin-7-G2- (2-amino-thiazol-4-yl) -2-methoxyimino-dedetam-7-3- (2-methyl-1H-imidazolo G4,5-c pyridine-5- ilmethyl) -3-cephem-4-carb-oxylate. Yield 96%.
NMR (DMSO-dJ: signals at (/ 9.9 (s, 1H); 9.5 (d, W); 8.85 (, W); 8.05 (d, 1H); 7.1 ( broad s, 2H); 6.66
(s, 1H); 5.7 (m, W); 5.1 (d, W); 3.75 (s, 3N); 2.7 (s, ZN).
Example Syn-7-f2- (2-amino-thiazol-4-yl) -2-methoxyimino acetates to -3- (1,2-dimethyl-1 H-imidazole C4,5- with pyridinium-5-ylmetsh1) -3- cefem-4-
carboxylate. Yield 80%.
there;
UV spectrum (EtOH)., Kc218, f 48500.
51MP spectrum (DMSO-d g):. signals at 9.8 (s, 1H); 9.5 (d, 1H); 9.1 Sd, Sh); 8.2 (d, 1H); 7.15 (broad s, 2H); 6.65 (s, 1H); 5.6 (m, 1H); 5.05 (m, 1H); 3.9 (s, ZN.); 3.75 (s, 3N); 2.7 (s, ZN).
Example 7. Sin-7-G2- (2-aminothiazol-4-yl) -2-methoxyiminoacetam- (2,3-dimesh1-ZN-imidazolo; 4.5IK spectrum (KBr): 1775 cm -lac
there;
UV spectrum (EtOH) 206, 38000;
M Theory 543; found 543.
NMR spectrum (flWCO-dg): signals at (, 9 (s, 1H); 9.5 (d, 1H); 9.3 (d, Sh); 8.1 (d, Sh); 7.15 (broad s, 2H); 6.7 (s, 1H); 5.7 (m, 1H); 5.1 (d, 1H); 3.95 (s, 3N); 3.8 (s, ZN); 2.8 (s, ZN).
(KBG): 1774 cm -lak-
(БЬОН) Л „,., 247, е 25500;
MSWSS
596; found 597.
1МР spectrum (DMSO-dg): signals at (Г 9.5 (d, 1H); 9.3 (s, 1H); 8.5 (d, ЗН); 7.8 (к, 2Н); 7 , 2 (broad s, 2H); 6.7 (s, IH); 5.7 (m, 1H); 5.1 (d, .1H); - 3.8 (s, 3N).
. PRI me R 9. Sin - 7 - 2 - (2-amino-thiaol-4 yl) -2-methoxy-amino acetate-3- (2-tZrenyl-1 H-imidazolo 4, pyridine-5 ylmethyl ) -3-cephem-4 - carboxy lat. Yield 620 mg.
IR spectrum (KVg): 1772 cm- / z-laktam;
U s spectrum (EtOH) ,,, 39500; M theory 591; found 591.
NMR spectrum (DMSO-c): signals at s / 9.5-7.5 (m, 8H); 7.1 (s, 2H); 6.7 (s, 1H); 5.7 (m, 1K); 5.15 (d, 1H); 3.8 (s, ZN).
Example 10. (notiazol-4-yl) -2-methoxyiminoacet-. AmidoJ-3- (2-aminooxazolo, REIDIUM - 4-CHI methyl) -3-cepheme-4 canister, 100% yield.
IR spectrum (KBG): 1772, 1695, 1656 cm | E-lactam;
UV spectrum (EtOH} H. ,,, t305, 235, - 315, f 22746.
NMR spectrum (DMSO-d): signals at, 5 (d, -1H); 9.05 (d, 1H); 8.1 (d, 1H); 7.33 (d, W); 7.1 (broad s, 2H);
6.7 (s, W}; 5.6 (n, 1H); 5.0 (d, W); 3.8 (s, 3N).
If p and m €. p 11. Sin-7 - 2- (2-amino thiazol-4-yl) -2-methoxyimine-acetamide-D3-3- (2-methyloxazolo C4,5-cJepi-dynium-5-sh1methyl) -3-11; efem -4-carboxylate. Yield 74%.
IR spectrum (KVg): 1776 cm / e lactam;
UV spectrum (E10H) L x203, 41500;
M theory 530; found 530.
NMR spectrum (DMSO-d): signals at, 2 (s, 1H): 9.5 (m, 2H); 8.5., (D, Ш); 5.6 (m, 1H); 5.0 (d, W);
3.8 (s, ZN); 2.8 (s, ZN). Example 12. Syn-7- 2- (2-aminothiazol-4-yl) -2-methoxyimino acetates to J-3- (thiazolo 4,5-c pyridinium-5-ylmethyl) -3-cephem-4-carboxyl-1. Yield 95%.
CQ sample (KVg): 1773 cm p-lactam;
 NMR spectrum (DMSO-dfe); signals at / 10.4 and 9.9 (d, 4H); 7.7 (s, Ш) -; 6.1 (d, 1H); 3.8 (s, ZN).
Example 13. Sin-7-C2- (2-aminothiazol-4-yoke) -2-methoxyiminoacyl (2-meth: lthiazolo 4,5-c) pyridite
five
 1623 cm-5-ylmethyl) -3-cephem-4-carboxylate. Yield 48%.
IR spectrum (KVg): 1777, 1674, 1623
lactam;
  UV spectrum (TLOE) 227, 260, f 21975;
NMR spectrum (flMCO-d): signals at s / 10.15 (s, Sh); 9.5 (d, 1H); 9.25 (d, 1H); 8.75 (d, 1H); - 5.6 (m, 1H); 5.0 (d, 1H); 3.8 (s, ZN); 2.95 (s, ZN).
Example 14. Syn-7- 2- (2-aminothiazol-4-yl) -2-methoxyimine cell-5 amido} -3- (2-ethylthiazol-4,5-c} pyridinium-5-ylmethyl) -3 -cephem-4-carboxy-l. at.
0
five
0
five
0
five
IR spectrum (KVg): 1772 cm / 3 laktam;
UV spectrum (EtOH):; 1 "x230, 46500;
 theory 559; found 560.
NMR spectrum (DMSO-d): signals At yi 10.15 (s, 1H); 9.35 (d, 1H); 8.8 (d, 1H); 5.6 (m, 1H); 5.0 (d, W); 3.8 (s, ZN); 3.3 (q, 2H); 1.4 (t, ЗН).
Example 15: Sin-7- 2- (2-aminothiazol-4-yl) -2-methoxyiminoacetate-amide-3- (2-aminothiazolo 5,4-b pyridinium-4-ylmetsh -3-cephem-4-carboxylate. The yield is 100%.
UV spectrum (EtOH) ks250, 25633.
Analysis calculated for C And, in%:
Theory: C 43.95; H 3.32; N 20.50; S-17.60.
Found: C 42.07; H 3.80; N 17.84; S 15.71 ,.
NMR spectrum (DMSO-d): signals at, 5 (d, W); 8.75 (m, 3N); 8.1 (d, 1H); 7.73 (m, W); 5.6 (m, 1H); 5.0 (d, W); 3.8 (s, ZN).
Titration (66% dimethylformamide vol / vol) pKdPri 4.0; 7.4; 10.7.
Example 16. CIN-7-C2- (2-ami-noti-olo-4-yl) -2-methoxyiminoacetate-amido-3- (2-methylthiaz, 4-c-pyridin-5-ylmethyl) -3-defem- 4-carboxylate.
UV spactre: 258 nm. 20563./
IR spectrum (KBG): 1774 cm H / 3 lactam).
 according to theory 546, found 546.
3-Bidyclic pyridine-methylthyne cephalosporins according to the invented invention are useful antibiotic substances. The compounds exhibit a high antibacterial
rial activity against a wide variety of positive and gram negative bacilli. The compounds are particularly effective against diseases caused by Streptococci, H. influenza, E. coli, Klebsiella, Enterobacter, Ralmonella and Serrotia.
The antibacterial activity of several representative compounds of the invention was evaluated in standard in vitro dilution tests on agar. The table shows the individual minimum inhibitory concentrations (MIC) in µg / ml for compounds when evaluating their activity against several gram-positive and rpaif-negative microorganisms. For comparison, the activity of the known compound ceftazidime (ceftazidime) is given.
Due to their high antibacterial activity, the compounds are particularly attractive.
For convenient oral administration, the compounds can be swept with any number of diluents, excipients, or 5 carriers used for oral preparations and formed into tablets, pills, lozenges, or encapsulated in gelatin capsules. Commonly used typical carriers, diluents
10 and fillers include potato starch, corn starch, sucrose, dextrose, microcrystalline cellulose, dicalcium phosphate, alginic acid, gum arabic, lubricants such as magnesium stearate, binders — tragacanth or gelatin, and substances flavoring, such as sweet butter, cherry or earthy flavor
2.0 or Wintergreen oil. The compounds can also be formulated as syrups or zlexierus using conventional diluents, such as fatty
15
oil, methyl or propyl-para-amino agents for the treatment of a variety of diseases -:.
 benzoic acids, suitable colors of bacterial origin. The amount of active antibiotic that needs to be administered for treatment will vary depending on the particular compound chosen, the severity of the disease that is being treated or wanted to be protected from, an individual course of treatment. and from related factors commonly encountered in treatment. However, compounds are usually administered at a dose of about 0.5-50 mg / kg body weight, and more preferably at a dose of about 1-10 mg / kg. Such amounts may be administered once a day or more often, as is necessary to treat a particular disease or a particular patient. A typical daily dose for an average adult will be 200-500 mg per day.
The antibiotic compounds of the invention are particularly parenteral active, but they can be prepared for any desired route of administration. Formulations for administration may contain about 0%, 1-95% by weight of the active cephalosporin antibiotic of the invention in admixture with a pharmaceutically acceptable carrier, diluent or vehicle for it. Typical preparations may contain 10-60% by weight of the active ingredient and more preferably 20-50%.
thirty
teli and flavoring substances. The compounds may also be formulated as an oral seal, a lozenge, or other suitable device, dp long-term controlled delivery of the active ingredient for a long time.
45
For intravenous, intramuscular or subcutaneous administration, the positions usually contain 0.1-20.0% of the active ingredient. Typical fillers, diluents and carriers. for parenteral formulations include isotonic saline, different
 Bled aqueous dextrose (for example, 5%), polyhydric aliphatic alcohols or mixtures thereof, for example glycerol, propyl glycol or polyethylene glycol. Parenteral solutions may also contain preservatives, such as phenethyl alcohol, methyl- and propyl-para-amino benzoic acids, and thimerosal. If desired, 0.05-0.20% by weight of an antioxidant, such as sodium metabisulfite or sodium bisulfite, may also be used. For intravenous use in preferred formulations, initial
The 55% concentration is 0.05-0.25 mg / ml of the active ingredient, and for intramuscular administration the preferred concentration of the active ingredient is 0.25-0.50 mg / ml.
50
For convenient oral administration, the compounds can be swept with any number of diluents, excipients or carriers used for oral preparations and formed into tablets, pills, lozenges, or encapsulated into gelatin capsules. Commonly used typical carriers, diluents
and fillers include potato starch, corn starch, sucrose, dextrose, microcrystalline cellulose, dicalcium phosphate, alginic acid, gum arabic, lubricants such as magnesium stearate, binders — tragacanth or gelatin, and odor agents such as sweet butter, cherry or earth flavoring
or wintergreen oil. The compounds can also be formulated as syrups or zlexierus using conventional diluents, such as fatty
teli and flavoring substances. The compounds may also be formulated as an oral seal, a lozenge, or other suitable device, dp long-term controlled delivery of the active ingredient for a long time.
45
For intravenous, intramuscular or subcutaneous administration, the positions usually contain 0.1-20.0% of the active ingredient. Typical fillers, diluents and carriers. for parenteral formulations include isotonic saline, different
 Bled aqueous dextrose (for example, 5%), polyhydric aliphatic alcohols or mixtures thereof, for example glycerol, propyl glycol or polyethylene glycol. Parenteral solutions may also contain preservatives, such as phenethyl alcohol, methyl- and propyl-para-amino benzoic acids, and thimerosal. If desired, 0.05-0.20% by weight of an antioxidant, such as sodium metabisulfite or sodium bisulfite, may also be used. For intravenous use in preferred formulations, initial
The 55% concentration is 0.05-0.25 mg / ml of the active ingredient, and for intramuscular administration the preferred concentration of the active ingredient is 0.25-0.50 mg / ml.
50
amount
1.0 g
100 ml
amount
500
mg
Examples of typical pharmaceutical preparations may include the following preparations.
Example 17. Preparation dp intravenously used:. Ingredient
Connection with measure 2
0.9% saline
solution
An intravenous solution can be prepared, for example, with a single dosage of antibiotic in a plastic bag or in a similar container, and add a diluent to the container before infusion.
Example 18. The preparation of oral suspension:
Ingredient
Example Compound-B
Sorbitol solution
(70% according to addition to pharmacopoeia (ClilA.)
Sodium benzoate
Saccharin
Vishneva Essenti
Distilled
water up to 100 ml
The sorbitol solution is added to 40 ml of distilled water and cephaloszorin suspendrate is added. Saccharin, sodium benzoate and essence are added and dissolved. The volume of the solution is made up to 100 ml by the addition of distilled water. As a milliliter of syrup contains 5 mg of cephalosporin antibiotic. This oral preparation is ideally suited for pediatric use.
Example 19. Getting capsules weighing 250 mg:
40 ml 150 mg 10 mg 50 mg
IngredientNumber
n, k
N-T-C-CONH
N

syn-isomer form, de E
one
an alkyl group containing from 1 to 4 carbon atoms, possibly substituted by a carboxyl group; Rj is hydrogen, amino, alkyl group containing from 1 to 4 carbon atoms, phenyl or 2-thienyl group
.ten
The compound of example 10250 mg Lactose 150 mg Corn starch 100 mg
0
five
0
five
01
five
0
500 mg
The ingredients are mixed until smooth and enclosed in gelatin capsules. Such capsules can be orally administered at a rate of approximately one capsule daily dp for the treatment of bacterial infections of the upper respiratory tract, including pharyngitis and tonsillitis.
Example 20. Getting paren ---. teral solution.
In a solution of 700 ml of propylene glycol and 200 ml of distilled water for injection, 20.0 g of the compound of Example 1 was dissolved as a hydrochloride salt. The pH of the solution was adjusted to 5.5 with hydrochloric acid, and the volume was adjusted to 1000 ml with distilled water. The preparation was sterilized, poured: 5.0 MP ampoules, each containing 2.0 ml (which meant 40 mg of the active ingredient) and sealed in a nitrogen atmosphere.
In addition, the present compounds can be administered rectally, for example, in suitably prepared suppositories. Pharmaceutically acceptable suppository preparations. can be prepared with an antibiotic compound and a composition for suppositories, such as cocoa butter, hydrogenated fats, glycerides or polyethylene glycols.

权利要求:
Claims (1)
[1]
Invention Formula
The method of obtaining cephalosporins of the general formula
: N
..
ygh
R,
or -S-, or -K-, where hydrogen or alkyl
a group containing from j to
4 carbon atoms; type is an integer equal to O, 1,
 2 or 3, with the sum m + n
equals 3,
characterized in that the compound of general formula II
cloacaeEB50,1250,25 0,060,06 0,030,06 0,03
SalmonellaX5140,1250,5 ((), 008 (l, 008 0.05., 008 0.03
Pseudoraonas X528281.0II24,
X2392222224
SerratiaX990,250,5 0,0150.06 0.060.03 0.03
13
Order 6166/57 Circulation .372: Subscription
VNIIPI USSR State Committee
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, st. Project, 4
1360587
4 Continuation of the table

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1360587A3|1987-12-15|Method of producing cephalosporins

---

CA1272714A|1990-08-14|Cephalosporin compounds and the production thereof

---

US4833134A|1989-05-23|Cephem compounds

---

JP2004509122A|2004-03-25|3- | -2-oxo-azetidine-1-sulfonic acid derivatives as antimicrobial agents

---

RU2183212C2|2002-06-10|Antibacterial cephalosporins, pharmaceutical composition based on thereof and method of treatment

---

US5574154A|1996-11-12|Process for the preparation of cephalosporanic compounds

---

US4692443A|1987-09-08|3-bicyclicpyridinium-methyl cephalosporins

---

EP0049119A2|1982-04-07|Cephalosporin derivatives, a process for their preparation and compositions containing them

---

GB2105719A|1983-03-30|Thieno and furopyridinium-substituted cephalosporin derivatives

---

KR102135230B1|2020-07-17|Cephem compounds, their production and use

---

IE54050B1|1989-05-24|Pyrazinium substituted cephalosporins

---

HU188586B|1986-04-28|Process for producing new cepheme derivatives

---

US4748172A|1988-05-31|3-bicyclicpyridinium-methyl cephalosporins

---

KR100248851B1|2000-04-01|A novel cephem derivative

---

GB2127812A|1984-04-18|7-substituted-3-vinyl-3-cephem compounda and processes for production of the same

---

EP0669336B1|2000-05-17|Novel cephem derivatives

---

GB2083461A|1982-03-24|7-beta-|-acetamido)-3-|methyl)-3-cephem-4-carboxylic acid and c1-c6 alkyl derivatives thereof

---

SU1418329A1|1988-08-23|7-acylamidecephalosporins manifesting antibacterial properties

---

KR100227009B1|1999-10-15|Novel cephem derivatives

---

WO1994006804A1|1994-03-31|Cephem compound, process for producing the same, and medicine containing the same

---

KR100696422B1|2007-03-20|Cephalosporines having cyclic aminoguanidine substituents as antibiotics

---

EP0186463A2|1986-07-02|Beta-lactam antibiotics

---

KR100481143B1|2005-04-08|Antibacterial substituted 7-acylamino-3-|methyl-cephalosporins and intermediates

---

EP0193858B1|1991-11-27|New 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same

---

EP0188781B1|1990-10-24|1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same

同族专利:

---

公开号 | 公开日

---

ES536728A0|1985-11-16|

---

EP0138552A2|1985-04-24|

---

GR80670B|1985-02-18|

---

GB2148289A|1985-05-30|

---

NZ209833A|1988-04-29|

---

DK489184D0|1984-10-12|

---

ZA847926B|1986-05-28|

---

PT79357B|1986-11-20|

---

AU3418984A|1985-04-26|

---

HU195512B|1988-05-30|

---

GB2181136A|1987-04-15|

---

GB8425453D0|1984-11-14|

---

ES8602816A1|1985-11-16|

---

GB2148289B|1987-09-23|

---

HUT35687A|1985-07-29|

---

GB2181136B|1988-05-25|

---

KR850002992A|1985-05-28|

---

EP0138552A3|1986-03-19|

---

IL73230D0|1985-01-31|

---

PT79357A|1984-11-01|

---

DK489184A|1985-04-18|

---

FI844000A0|1984-10-11|

---

PH21040A|1987-07-03|

---

FI844000L|1985-04-18|

---

CA1225390A|1987-08-11|

---

GB8627171D0|1986-12-10|

---

JPS60105685A|1985-06-11|

---

AU574107B2|1988-06-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE3118732A1|1981-05-12|1982-12-02|Hoechst Ag, 6000 Frankfurt|CEPHALOSPORINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION|

---

GR76701B|1981-09-08|1984-08-29|Lilly Co Eli|

---

DE3207840A1|1982-03-04|1983-09-15|Hoechst Ag, 6230 Frankfurt|"CEPHALOSPORINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF"|

---

US4500526A|1982-06-28|1985-02-19|Bristol-Myers Company|Cephalosporin derivatives|

---

DE3374410D1|1982-06-28|1987-12-17|Bristol Myers Co|Cephalosporin derivatives, a process for the manufacture thereof and pharmaceutical compositions containing said derivatives|PH22107A|1984-06-07|1988-06-01|Takeda Chemical Industries Ltd|3-pyrazolopyrdinium cephem compounds|

---

US4734408A|1986-12-17|1988-03-29|Eli Lilly And Company|Crystalline cephalosporin antibiotic salts and solvates|

---

EP0304858A3|1987-08-25|1989-12-20|Takeda Chemical Industries, Ltd.|Cephem compounds, their production and use|

---

TW526202B|1998-11-27|2003-04-01|Shionogi & Amp Co|Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity|

---

AT412214B|1999-05-05|2004-11-25|Sandoz Ag|Preparation of beta-lactam derivatives used as antibacterial agents by reacting cephalosporanic acid derivative with imine compound, then thiourea compound|

---

GB0215293D0|2002-07-03|2002-08-14|Rega Foundation|Viral inhibitors|

---

US20050222198A1|2003-12-22|2005-10-06|K.U. Leuven Research & Development, Gerhard Puerstinger And Gilead Sciences, Inc.|Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment|

---

DE602005013580D1|2004-12-21|2009-05-07|Leuven K U Res & Dev|IMIDAZOE4,5-CYPYRIDINE COMPOUND AND METHOD FOR ANTIVIRAL TREATMENT|

---

MX2009000235A|2006-07-07|2009-01-23|Gilead Sciences Inc|Novel pyridazine compound and use thereof.|

---

AU2008275756B2|2007-07-06|2012-01-19|Gilead Sciences, Inc.|Crystalline pyridazine compound|

---

US20140275000A1|2013-03-15|2014-09-18|Cubist Pharmaceuticals, Inc.|Ceftolozane pharmaceutical compositions|

---

US9872906B2|2013-03-15|2018-01-23|Merck Sharp & Dohme Corp.|Ceftolozane antibiotic compositions|

---

KR102226197B1|2013-03-15|2021-03-11|머크 샤프 앤드 돔 코포레이션|Ceftolozane antibiotic compositions|

---

ES2800603T3|2013-09-09|2021-01-04|Merck Sharp & Dohme|Treatment of infections with ceftolozane / tazobactam in patients with renal impairment|

---

US8906898B1|2013-09-27|2014-12-09|Calixa Therapeutics, Inc.|Solid forms of ceftolozane|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US54261983A| true| 1983-10-17|1983-10-17|

---